Alexion Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Alexion Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Alexion Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Alexion Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Alexion Pharmaceuticals Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP4284361A1 | Application | Neuartige formulierung zur behandlung von erkrankungen oder störungen im zusammenhang mit dem kupferstoffwechsel | A61K31/14; A61K33/00; A61P3/00 | December 06, 2023 |
| EP3873602B1 | Grant | Subcutane dosierung und ztudienung von anti-c5-antikörpern zur behandlung der paroxysmalen nicht-turnalen hämoglobinurie (PNH) | A61K2039/505; A61K2039/54; A61K2039/545; A61P7/00; C07K16/18; C07K2317/52; C07K2317/565; C07K2317/92; C07K2317/94 | December 06, 2023 |
| FI3658184T3 | Grant | High concentration anti-c5 antibody formulations | A61K2039/505; A61K39/39591; A61K47/02; A61K47/183; A61K47/26; A61K9/0019; A61K9/08; A61P13/00; A61P13/02; C07K16/18; C07K2317/526; C07K2317/565; C07K2317/94; Y02A50/30 | November 30, 2023 |
| US20230383276A1 | Application | Process for making recombinant antidote to factor xa inhibitor | C12N2510/02; C12N9/64; C12N9/6432; C12N9/6454; C12Y304/21006 | November 30, 2023 |
| AU2022283254A1 | Application | Kidney active fusion proteins and methods of treatment using the same | November 30, 2023 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer